Int. J. Mol. Sci. 2015, 16(8), 19836-19850; https://doi.org/10.3390/ijms160819836
Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy
1
Asahi Matsumoto Hospital, Kokuramimami-ku Tsuda, Kitakyushu-shi 800-0242, Japan
2
Shared-Use Research Center, University of Occupational and Environmental Health School of Medicine, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan
3
Department of Neurosurgery, University of Occupational and Environmental Health School of Medicine, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan
4
Department of Gynecology, University of Occupational and Environmental Health School of Medicine, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan
5
Department of Gastroenterological Surgery, School of Medicine, Fukuoka University, Fukuoka 814-0180, Japan
6
Department of Radiology, Beppu Hospital, Kyushu University, Beppu 874-0838, Japan
7
Department of Pathology and Cell Biology, University of Occupational and Environmental Health School of Medicine, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan
8
Second Department of Internal Medicine, University of Occupational and Environmental Health School of Medicine, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan
9
Department of Occupational Pneumology, Institute of Industrial Ecological Science, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu-shi 807-8555, Japan
*
Author to whom correspondence should be addressed.
Academic Editors: Lars Olson, Jaime M. Ross and Giuseppe Coppotelli
Received: 16 May 2015 / Revised: 28 July 2015 / Accepted: 7 August 2015 / Published: 20 August 2015
(This article belongs to the Special Issue Mitochondrial Dysfunction in Ageing and Diseases)
Abstract
Mitochondria are important cellular organelles that function as control centers of the energy supply for highly proliferative cancer cells and regulate apoptosis after cancer chemotherapy. Cisplatin is one of the most important chemotherapeutic agents and a key drug in therapeutic regimens for a broad range of solid tumors. Cisplatin may directly interact with mitochondria, which can induce apoptosis. The direct interactions between cisplatin and mitochondria may account for our understanding of the clinical activity of cisplatin and development of resistance. However, the basis for the roles of mitochondria under treatment with chemotherapy is poorly understood. In this review, we present novel aspects regarding the unique characteristics of the mitochondrial genome in relation to the use of platinum-based chemotherapy and describe our recent work demonstrating the importance of the mitochondrial transcription factor A (mtTFA) expression in cancer cells. View Full-TextKeywords:
mtTFA; mtDNA; cisplatin; cancer chemotherapy; prognosis
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Kohno, K.; Wang, K.-Y.; Takahashi, M.; Kurita, T.; Yoshida, Y.; Hirakawa, M.; Harada, Y.; Kuma, A.; Izumi, H.; Matsumoto, S. Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. Int. J. Mol. Sci. 2015, 16, 19836-19850.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert